• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Oncology
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
    • Drug Development
    • Small Molecule Research & Development
    • Oncology
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • Outsourcing Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Oncology
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
    • Drug Development
    • Small Molecule Research & Development
    • Oncology
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • Outsourcing Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

Deals

The latest pharma deals — mergers, acquisitions, licensing agreements, and partnerships shaping the business of drug development worldwide.

Biogen AAIC
Biotech

Biogen inks $411M pact for TrimTech’s protein degrader skills

TrimTech’s platform could help clear proteins associated with diseases such as Alzheimer’s, Parkinson’s and Huntington’s.
Michael Gibney Nov 16, 2026 10:00am
Eli Lilly booth at ASCO 2026

Lilly gets fresh myelofibrosis option via $1.5B Calytrix buyout

Nov 16, 2026 9:49am
JNJ

J&J pays $2.2B upfront for Ollin to challenge Roche’s Vabysmo

Nov 16, 2026 9:40am
Sunset

DNA med-focused biotech Seawolf surfaces with $1.2B Sanofi pact

Nov 16, 2026 5:00am
Charles River booth at AACR 2026

Charles River pays $470M for 2 Frontage labs in Pennsylvania

Nov 13, 2026 11:00am
China US deals flags MA

Vor pays RemeGen $10M for long-acting autoimmune drug successor

Nov 12, 2026 10:16am
Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2026 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings